Bicalutamide News and Research

RSS
Long-term hormone therapy does more harm than good for men with low PSAs after prostate surgery

Long-term hormone therapy does more harm than good for men with low PSAs after prostate surgery

Pre-SRT PSA could serve as prognostic and predictive biomarker of benefit from hormone therapy

Pre-SRT PSA could serve as prognostic and predictive biomarker of benefit from hormone therapy

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

Radiation plus hormones offers best outcomes for localised prostate cancer

Radiation plus hormones offers best outcomes for localised prostate cancer

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Emotional stress can reduce prostate cancer drugs’ effectiveness

Emotional stress can reduce prostate cancer drugs’ effectiveness

Adamis' APC-300 inhibits growth of prostate cancer cells

Adamis' APC-300 inhibits growth of prostate cancer cells

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

KAPIDEX to be marketed as DEXILANT in the U.S.

KAPIDEX to be marketed as DEXILANT in the U.S.

Heartburn drug Kapidex to be marketed under new name Dexilant

Heartburn drug Kapidex to be marketed under new name Dexilant

Astellas enters into agreement with Medivation to develop MDV3100

Astellas enters into agreement with Medivation to develop MDV3100

New therapy for metastatic prostate cancer shows promise

New therapy for metastatic prostate cancer shows promise

New therapy for metastatic prostate cancer shows promise

New therapy for metastatic prostate cancer shows promise

New way to treat advanced prostate cancer, potentially more effective, fewer side effects

New way to treat advanced prostate cancer, potentially more effective, fewer side effects

Hormonal nutritional supplements might speed prostate cancer progression

Hormonal nutritional supplements might speed prostate cancer progression